Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on EPS, Stock Down 4.52%

Corvus Pharmaceuticals reported a loss per share of $0.58, but there were no revenue figures provided. The stock reacted negatively, declining by 4.52%. The lack of guidance or detailed commentary from management may have contributed to investor uncertainty.